|
gptkbp:instance_of
|
gptkb:Clinical_Trials
|
|
gptkbp:aims_to
|
reduce cardiovascular risk
|
|
gptkbp:analyzes
|
safety profile of liraglutide
|
|
gptkbp:case_analysis
|
pharmaceutical research
|
|
gptkbp:completed
|
gptkb:2014
|
|
gptkbp:conducted
|
gptkb:Europe
gptkb:Asia
gptkb:North_America
|
|
gptkbp:contributes_to
|
understanding of diabetes management
|
|
gptkbp:critical_analysis
|
understanding diabetes complications
|
|
gptkbp:evaluates
|
effectiveness of liraglutide
|
|
gptkbp:has
|
patient-reported outcomes
multiple publications
long-term follow-up
adverse event monitoring
|
|
gptkbp:has_a_focus_on
|
health policy discussions
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
FREEDOM trial
|
|
gptkbp:includes
|
placebo group
|
|
gptkbp:involves
|
multiple centers
|
|
gptkbp:is_a_double-blind_study
|
nan
|
|
gptkbp:is_a_foundation_for
|
future diabetes therapies
|
|
gptkbp:is_a_key_study_in
|
diabetes pharmacotherapy
|
|
gptkbp:is_a_key_trial_for
|
liraglutide efficacy
|
|
gptkbp:is_a_landmark_study_for
|
diabetes research
|
|
gptkbp:is_a_multi-national_study
|
nan
|
|
gptkbp:is_a_phase_3_trial
|
nan
|
|
gptkbp:is_a_pivotal_trial_for
|
liraglutide approval
|
|
gptkbp:is_a_randomized_trial
|
nan
|
|
gptkbp:is_a_reference_for
|
clinical outcomes
future diabetes trials
|
|
gptkbp:is_a_significant_trial_for
|
chronic disease management
|
|
gptkbp:is_a_source_of
|
clinical evidence
|
|
gptkbp:is_a_subject_of
|
systematic reviews
meta-analysis
|
|
gptkbp:is_a_vital_research_effort_for
|
improving patient outcomes
|
|
gptkbp:is_analyzed_in
|
statistical methods
|
|
gptkbp:is_associated_with
|
weight loss
improved glycemic control
|
|
gptkbp:is_cited_in
|
clinical research articles
|
|
gptkbp:is_designed_to
|
assess long-term effects
|
|
gptkbp:is_funded_by
|
gptkb:pharmaceuticals
|
|
gptkbp:is_informed_by
|
clinical guidelines for diabetes treatment
|
|
gptkbp:is_linked_to
|
improved quality of life
|
|
gptkbp:is_part_of
|
evidence-based medicine
larger research program
|
|
gptkbp:is_recognized_by
|
medical community
|
|
gptkbp:is_referenced_in
|
subsequent studies
|
|
gptkbp:is_relevant_to
|
gptkb:healthcare_professionals
patients with diabetes
|
|
gptkbp:is_significant_for
|
public health
|
|
gptkbp:measures
|
cardiovascular outcomes
|
|
gptkbp:model
|
clinical trial design
|
|
gptkbp:notable_contributor
|
clinical practice improvements
diabetes care advancements
|
|
gptkbp:performance
|
treatment efficacy
|
|
gptkbp:published_in
|
gptkb:The_New_England_Journal_of_Medicine
|
|
gptkbp:recruitment
|
adults with type 2 diabetes
|
|
gptkbp:registration
|
gptkb:Clinical_Trials.gov
|
|
gptkbp:reported_by
|
medical conferences
|
|
gptkbp:research
|
type 2 diabetes
|
|
gptkbp:results_indicate
|
liraglutide reduces major adverse cardiovascular events
|
|
gptkbp:sponsored_by
|
gptkb:Novo_Nordisk
|
|
gptkbp:started_in
|
gptkb:2010
|
|
gptkbp:uses
|
randomized controlled design
|
|
gptkbp:bfsParent
|
gptkb:Prolia
|
|
gptkbp:bfsLayer
|
5
|